Venus Remedies Limited (VENUSREM.BO)
INR 303.0
(-0.61%)
INR 303.0
(-0.61%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.91 Billion INR | 8.69% |
| 2022 | 5.53 Billion INR | -7.56% |
| 2021 | 5.98 Billion INR | 9.22% |
| 2020 | 5.48 Billion INR | 61.53% |
| 2019 | 3.39 Billion INR | 6.91% |
| 2018 | 3.17 Billion INR | -14.09% |
| 2017 | 3.69 Billion INR | -6.76% |
| 2016 | 3.96 Billion INR | -4.5% |
| 2015 | 4.14 Billion INR | -10.47% |
| 2014 | 4.63 Billion INR | -13.59% |
| 2013 | 5.36 Billion INR | 14.61% |
| 2012 | 4.67 Billion INR | 14.46% |
| 2011 | 4.08 Billion INR | 12.6% |
| 2010 | 3.63 Billion INR | 15.41% |
| 2009 | 3.14 Billion INR | 16.72% |
| 2008 | 2.69 Billion INR | 23.44% |
| 2007 | 2.18 Billion INR | 49.07% |
| 2006 | 1.46 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.08 Billion INR | -44.35% |
| 2024 Q2 | 1.67 Billion INR | 54.18% |
| 2023 FY | 6.01 Billion INR | 8.69% |
| 2023 Q1 | 951.5 Million INR | -38.02% |
| 2023 Q3 | 1.43 Billion INR | -14.49% |
| 2023 Q4 | 1.95 Billion INR | 36.08% |
| 2023 Q2 | 1.67 Billion INR | 76.27% |
| 2022 Q1 | 1.43 Billion INR | 0.81% |
| 2022 Q4 | 1.53 Billion INR | 31.32% |
| 2022 FY | 5.53 Billion INR | -7.56% |
| 2022 Q3 | 1.16 Billion INR | -16.43% |
| 2022 Q2 | 1.39 Billion INR | -2.23% |
| 2021 Q2 | 2.02 Billion INR | 56.04% |
| 2021 Q4 | 1.41 Billion INR | 14.15% |
| 2021 Q1 | 1.29 Billion INR | 16.56% |
| 2021 FY | 5.98 Billion INR | 9.22% |
| 2021 Q3 | 1.24 Billion INR | -38.62% |
| 2020 Q3 | 1.21 Billion INR | -3.28% |
| 2020 Q2 | 1.26 Billion INR | -33.21% |
| 2020 Q4 | 1.11 Billion INR | -8.67% |
| 2020 Q1 | 1.88 Billion INR | 141.26% |
| 2020 FY | 5.48 Billion INR | 61.53% |
| 2019 Q3 | 968.59 Million INR | 10.2% |
| 2019 Q2 | 878.94 Million INR | 19.35% |
| 2019 Q4 | 782.33 Million INR | -19.23% |
| 2019 Q1 | 736.46 Million INR | -14.44% |
| 2019 FY | 3.39 Billion INR | 6.91% |
| 2018 Q1 | 669.42 Million INR | 0.0% |
| 2018 FY | 3.17 Billion INR | -14.09% |
| 2018 Q4 | 860.74 Million INR | 13.24% |
| 2018 Q3 | 760.11 Million INR | -14.0% |
| 2018 Q2 | 883.88 Million INR | 32.04% |
| 2017 FY | 3.69 Billion INR | -6.76% |
| 2016 FY | 3.96 Billion INR | -4.5% |
| 2016 Q4 | 798.21 Million INR | 0.0% |
| 2015 FY | 4.14 Billion INR | -10.47% |
| 2014 FY | 4.63 Billion INR | -13.59% |
| 2013 Q1 | 1.26 Billion INR | -5.4% |
| 2013 Q3 | 1.31 Billion INR | 0.0% |
| 2013 Q4 | 1.52 Billion INR | 16.27% |
| 2013 FY | 5.36 Billion INR | 14.61% |
| 2012 Q1 | 1.12 Billion INR | 0.0% |
| 2012 FY | 4.67 Billion INR | 14.46% |
| 2012 Q2 | 1.1 Billion INR | -1.45% |
| 2012 Q3 | 1.11 Billion INR | 1.1% |
| 2012 Q4 | 1.33 Billion INR | 19.93% |
| 2011 FY | 4.08 Billion INR | 12.6% |
| 2010 FY | 3.63 Billion INR | 15.41% |
| 2009 FY | 3.14 Billion INR | 16.72% |
| 2008 FY | 2.69 Billion INR | 23.44% |
| 2007 FY | 2.18 Billion INR | 49.07% |
| 2006 FY | 1.46 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ipca Laboratories Limited | 76.22 Billion INR | 92.241% |
| Laurus Labs Limited | 50.01 Billion INR | 88.175% |
| Ajanta Pharma Limited | 42.08 Billion INR | 85.947% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -40.41% |
| Sigachi Industries Limited | 3.98 Billion INR | -48.249% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 53.825% |
| Achyut Healthcare Limited | 61.36 Million INR | -9537.596% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -682.907% |
| Medico Remedies Limited | 1.44 Billion INR | -308.119% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -466.876% |
| Bal Pharma Limited | 3.39 Billion INR | -74.356% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 74.096% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 67.422% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -128.144% |
| Alpa Laboratories Limited | 1.08 Billion INR | -443.917% |
| NATCO Pharma Limited | 40.02 Billion INR | 85.221% |
| Aarti Drugs Limited | 25.28 Billion INR | 76.609% |
| Gufic Biosciences Limited | 8.06 Billion INR | 26.68% |
| Lupin Limited | 200.1 Billion INR | 97.044% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 97.94% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 96.891% |
| FDC Limited | 19.42 Billion INR | 69.559% |
| Windlas Biotech Limited | 6.3 Billion INR | 6.261% |
| Ind-Swift Limited | 5.02 Billion INR | -17.709% |
| Eris Lifesciences Limited | 20.09 Billion INR | 70.562% |
| Indoco Remedies Limited | 17.89 Billion INR | 66.948% |
| Valiant Laboratories Limited | 1.82 Billion INR | -224.87% |
| Hester Biosciences Limited | 3.04 Billion INR | -94.207% |
| Strides Pharma Science Limited | 40.51 Billion INR | 85.4% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 52.24% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 23.213% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 64.88% |
| Shilpa Medicare Limited | 11.51 Billion INR | 48.641% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 98.78% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 72.088% |
| Suven Life Sciences Limited | 116.92 Million INR | -4958.194% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 83.025% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -24.932% |
| RPG Life Sciences Limited | 5.82 Billion INR | -1.615% |
| Mankind Pharma Limited | 103.34 Billion INR | 94.277% |
| Piramal Pharma Limited | 81.71 Billion INR | 92.762% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 94.423% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 90.323% |
| Medicamen Biotech Limited | 1.79 Billion INR | -229.855% |
| Hikal Limited | 17.84 Billion INR | 66.858% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 94.993% |
| Unichem Laboratories Limited | 16.57 Billion INR | 64.315% |
| Novartis India Limited | 3.35 Billion INR | -76.515% |
| Sequent Scientific Limited | 13.69 Billion INR | 56.82% |
| Wanbury Limited | 5.75 Billion INR | -2.745% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 43.744% |
| Wockhardt Limited | 27.89 Billion INR | 78.793% |
| Themis Medicare Limited | 3.81 Billion INR | -54.927% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -183.394% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 91.176% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 97.881% |
| Divi's Laboratories Limited | 78.45 Billion INR | 92.461% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 48.626% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 54.347% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -1073.011% |
| Granules India Limited | 45.06 Billion INR | 86.875% |
| Alkem Laboratories Limited | 126.67 Billion INR | 95.331% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -1377.32% |
| Brooks Laboratories Limited | 794.86 Million INR | -644.092% |
| Megasoft Limited | 373.95 Million INR | -1481.615% |
| ZIM Laboratories Limited | 3.67 Billion INR | -60.972% |
| Neuland Laboratories Limited | 15.58 Billion INR | 62.052% |
| Morepen Laboratories Limited | 17.01 Billion INR | 65.248% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -283.131% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -60.461% |